



IN THE UNITED STATES PATENT OFFICE

Application Serial No. 07/838,675

Our Ref. : PT-1039

Applicants : RUDOLF EDGAR FALK Agent  
and SAMUEL SIMON ASCULAI

200<sup>00</sup> 126 153  
8/1/93  
Act w/att  
RECEIVED  
MAR 25 1993  
Ivor M. Hughes,  
Suite 200, GROUP 150  
175 Commerce  
Valley Drive West,  
Thornhill, Ontario.  
L3T 7P6

Title : TREATMENT OF DISEASE  
EMPLOYING HYALURONIC  
ACID AND NSAIDS

Inventors : Rudolf Edgar Falk And  
Samuel Simon Asculai

Examiner : NATHAN M. NUTTER

Group Art Unit: 1503

March 5, 1993

The Commissioner of Patents,  
UNITED STATES PATENT OFFICE,  
Washington, D.C. 20231  
U.S.A.

Dear Sir:

**INFORMATION DISCLOSURE  
STATEMENT**

Applicants and the undersigned are aware of "patents, publication, or other information" which they believe may be material to the examination of the above-identified application. Copies of these items, and one sheet of Form PTO-1449 listing them, are submitted herewith pursuant to 37 C.F.R. §§ 1.97-1.99 and to the duty of disclosure set forth in 37 C.F.R. § 1.56.

070 AA 03/22/93 07838675

1 126

200.00 CK

Although this Information Disclosure Statement identifies references which may be "material," it is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" (within the meaning of 35 U.S.C. § 102 103) as to the invention disclosed and claimed in this application unless specifically

designated as such. Moreover, no representation is intended as to the relative relevance of any portion of the references or as to the relevance among references, whether cited in this Statement or elsewhere.

In accordance with 37 C.F.R. § 1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a novelty search has been made or that no other information which may be material (as defined in 37. C.F.R. § 1.56(a)) exists.

#### **UNITED STATES PATENTS**

4,141,973  
4,303,676  
4,582,865  
4,636,524  
4,684,627  
4,711,780  
4,725,585  
4,736,024  
4,755,544  
4,795,741  
4,801,619  
4,808,576  
4,814,176  
4,840,941  
4,851,521  
4,937,254  
4,957,744  
4,965,353  
4,970,298  
5,095,037  
5,166,331  
07/338,106

#### **CANADIAN PATENTS**

1,205,031  
1,240,929  
2,031,880

## FOREIGN PATENTS

769 287 EP  
0 138 572 EP  
0 179 442 EP  
0 197 718 EP  
0 208 623 EP  
0 216 453 EP  
0 224 987 EP  
0 240 098 EP  
0 244 178 EP  
0 265 116 EP  
0 270 317 EP  
0 285 357 EP  
0 287 210 EP  
0 295 092 EP  
0 296 740 EP  
0 312 208 EP  
0 341 745 EP  
14534/88 AU  
15456/88 AU  
17459/88 AU  
29145/89 AU

1287041 Japan - Abstract only  
62201825 Japan - English translation  
62287041 Japan - English translation  
63/045223 Japan - English Abstract  
61000017 Japan - English Abstract  
WO 88/07060 PCT  
WO 89/07932 PCT

WO 91/04058 International Search Report and Written Opinion

## DOCUMENTS

Sandra Blakeslee, "Solid cores of tumors keeping out best drugs", July 8, 1989 edition of the Globe and Mail, Toronto, Ontario, Page D4.

Pam Harrison, "Toxic drug tamed but still potent" Ontario Medicine, Volume 8, No. 16 dated August 21, 1989, Page 1.

The Merck Index Eleventh Edition, Centennial Edition, Hyaluronic Acid formulations, Pages 751 and 752.


Alan R. Liss, Inc., Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, Immunity to Cancer II.

Goodwin, J.S. Prostaglandin E and Cancer Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, Augmentive Agents in Cancer Therapy, Raven Press, New York, (1981).

Dr. Samuel Asculai, "Inactivation of Herpes Simples Viruses by Nonionic Surfactants", Antimicrobial Agents and Chemotherapy, April 1978, pp. 686-690.

Chemical Abstracts, Vol. 76, No. 10; W. E. Sneader; "Possible Mechanism for action of DMSO on Percutaneous absorption", J. Pharm. Pharmacol. 1971, 23 (Suppl).

Respectfully submitted,



IVOR M. HUGHES  
Agent for Applicants  
Registration No. 27,759  
1-800-265-6836

jv  
Enclosure